Background-We evaluated patients undergoing percutaneous coronary intervention to assess the predictive value of high-sensitivity C-reactive protein (hs-CRP) and pregnancy-associated plasma protein-A (PAPP-A) on adverse cardiac outcomes and the effect of antiplatelet therapy on these outcomes.
A therosclerosis is a complex process that involves inflammation of the arterial wall. 1 In recent years, increasing data have demonstrated a clear relationship between elevated inflammatory biomarkers and the risk of future atherothrombotic events in multiple clinical settings. [2] [3] [4] [5] [6] [7] However, little is known about whether and how biomarkers should be used to adjust medical therapy in patients with coronary atherosclerosis. Only the Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial 8 has shown a clinical benefit to therapy based on an inflammatory biomarker.
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High sensitivity C-reactive protein (hs-CRP) is one of the most studied biomarkers in coronary disease and has been found in several retrospective analyses to be potentially useful in identifying patients who would benefit most from treatment with aspirin 9 and statins 10 in the primary prevention of acute coronary events. In patients with known coronary artery disease, greater decreases in hs-CRP levels with statin therapy are associated with a greater reduction in recurrent coronary events 11 and in the rate of coronary atherosclerosis progression. 12 One observational study found that initiating clopidogrel before a percutaneous coronary intervention (PCI) was associated with a reduction in 30-day death or myocardial infarction (MI) almost exclusively for those patients with elevated baseline hs-CRP levels. 13 Clopidogrel has also been shown to reduce the periprocedural rise in hs-CRP in patients undergoing PCI. 14 The association between pre-PCI hs-CRP levels and long-term outcomes, as well as the effect of prolonged dual antiplatelet therapy on these outcomes, has not previously been explored.
Pregnancy-associated plasma protein-A (PAPP-A) is a matrix metalloproteinase that is expressed abundantly in ruptured and eroded atherosclerotic plaques. It is elevated in patients with an acute coronary syndrome, 15 and increasing levels are associated with recurrent cardiovascular events in such patients independent of troponin levels. 16, 17 PAPP-A has also been shown to predict future episodes of acute coronary syndrome and death in patients with stable coronary disease. 2 As with hs-CRP, data are lacking regarding the association between PAPP-A levels and long-term outcomes after PCI and the effect of dual antiplatelet therapy on these outcomes.
To explore the predictive value of baseline hs-CRP and PAPP-A levels in determining outcomes after PCI and the effect of antiplatelet therapy on these outcomes, we evaluated patients in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Methods
We performed this post hoc analysis of the CREDO trial, a prospective, randomized, double-blind, placebo-controlled, multicenter trial in which 2116 patients undergoing planned PCI or thought to be at high likelihood to undergo PCI were enrolled. 18 Patients were randomized between 3 and 24 hours before planned PCI to receive a 300 mg loading dose of clopidogrel or placebo. All patients subsequently received 75 mg of clopidogrel beginning at the time of the procedure and then daily through day 28. Thereafter, patients randomized to clopidogrel loading continued to receive clopidogrel through 12 months, whereas those in the control group were given placebo. All patients received daily aspirin therapy. The primary end point was the 1-year composite incidence of all-cause death, MI, or stroke. The 28-day primary end point was the composite incidence of all-cause death, MI, or urgent target vessel revascularization. Secondary end points included individual components of the composite primary end points.
Through the prospectively designed Insulin Resistance Substudy of CREDO, baseline blood samples were drawn on 1472 patients. Of these, sufficient blood samples were available to test hs-CRP on 1468 patients and PAPP-A on 1096. The lower number of PAPP-A testing was the result of inadequate sample volume for PAPP-A after hs-CRP testing was performed. Specimens were collected at each clinical site in the fasting state and allowed to clot; the serum was removed and frozen within 1 hour of collection. Sera were sent on dry ice to a core laboratory at the Cleveland Clinic. All samples were stored at Ϫ80°C. Immunoturbido-metric method (Roche Tina-quant [latex]) was used to determine hs-CRP. PAPP-A levels were determined using a biotin-tyramide-amplified enzyme immunoassay.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Statistical Analysis
To maintain consistency with previous literature and clinical guidelines, levels of hs-CRP and PAPP-A were divided into tertiles for data analyses. 19, 20 The Kaplan-Meier method was used to estimate the incidence of the composite end point of death, MI, or stroke for up to 1 year and the composite end point of death, MI, or urgent target vessel revascularization through 28 days postrandomization within the tertiles of hs-CRP and PAPP-A. The incidence of each component of the composite end point was also estimated. The treatment effect of clopidogrel was assessed within each tertile. Exploratory analyses suggested similar unadjusted hazard ratios (HR) for treatment within the second and third tertiles of both hs-CRP and PAPP-A. As a result, the second and third tertiles for each biomarker were combined for formal data analyses; except where indicated otherwise, all data presented in this manuscript are from formal data analyses in which the second and third tertiles were combined. The log-rank test was used to compare Kaplan-Meier results.
Comparisons of the continuous baseline characteristics (first tertile versus combined second and third tertiles) were made using the 2-sample t test. Comparisons of categorical baseline characteristics were made using the 2 test of association. A Spearman rank correlation coefficient was calculated to summarize the relationship between hs-CRP and PAPP-A.
A secondary analysis was performed looking at the combination of hs-CRP and PAPP-A to assess the effect of having both biomarkers elevated. Specifically, incidence estimates for the 1-year and 28-day composite end points were generated for patients who were in the highest 2 tertiles of both hs-CRP and PAPP-A, and for patients in the first tertile for at least 1 of the biomarkers.
Multivariable analyses were performed using Cox proportional hazards models to determine whether hs-CRP and PAPP-A levels, while adjusting for treatment and other covariates, predict the 1-year end point. One of these models looked at hs-CRP (second or third tertile versus first), the second at PAPP-A (second or third tertile versus first), and the third at both biomarkers (second or third tertile for both versus at least 1 biomarker in the first).
Baseline demographics or risk factors that differed significantly across tertiles of hs-CRP or PAPP-A were used for adjustment in the multivariable model. Additionally, variables that were significantly associated with the primary end point were also retained in the model. These variables include gender, white race, body mass index, smoking, and history of diabetes, hypertension, hyperlipidemia, and coronary artery bypass graft. Creatinine clearance and use of any statin were further added based on scientific expectation that they might confound the relationship between biomarkers and end points. 8, 21 Interactions of the biomarkers with treatment were also tested. Specifically, the interaction was assessed by including in the proportional hazards regression model a term that is the product of the variable indicating treatment status (1ϭclopidogrel, 0ϭplacebo) and the variable indicating membership in the second or third tertile (1ϭsecond or third tertile, 0ϭfirst tertile). A test for interaction is a test of whether the regression model coefficient for this product term is nonzero. P values Ͻ0.05 were considered statistically significant. All analyses were performed using the SAS software version 9.0 (SAS Institute).
Results
The mean hs-CRP level was 7.9 mg/L (SD 5.5) with a median of 2.8 mg/L (interquartile range [1.1 to 7.3 mg/L]). Tertiles for hs-CRP were Ͻ1.5, 1.5 to 5.1, and Ͼ5.1 mg/L. The mean PAPP-A level was 3.5 mIU/L (SD 8.7) with a median of 1.1 mIU/L (interquartile range [0.64 to 2.0 mIU/L]). PAPP-A tertiles were Ͻ0.79, 0.79 to 1.6, and Ͼ1.6 mIU/L. There was no clinically important correlation between hs-CRP and PAPP-A levels (rϭϪ0.13, PϽ0.001).
Baseline demographics based on tertile of inflammatory markers are outlined in Table 1 . Patients in the highest 2 tertiles of hs-CRP were more often women, obese, hypertensive or smoking, more likely to use a calcium channel blocker, and less likely to take a statin than patients in the lowest hs-CRP tertile. Patients in the highest 2 tertiles of PAPP-A were more often men, less likely to have diabetes mellitus, hypertension, or hyperlipidemia, and less likely to be taking aspirin, a statin, an angiotensin-converting enzyme inhibitor, or a calcium channel blocker than those in the lowest tertile. Patients with both biomarkers elevated were more often smokers and less likely to have hyperlipidemia or use a statin than patients low on at least 1 biomarker.
CRP and 28-Day and 1-Year Outcomes
Increased levels of hs-CRP at baseline were associated with worse outcomes ( Table 2 ). The 1-year primary end point occurred less often in the first tertile than in the second and third (6.4%, 11.1%, and 11. 7% respectively, Pϭ0.01). The unadjusted HRs were similar for the 1-year primary end point for patients in the second (HRϭ1.8, 95% CI [1.1, 2.8], Pϭ0.01) and third (HRϭ1.9,[1.2, 2.9], Pϭ0.005) tertiles compared with the first tertile. As a result of the similar raw event rates and unadjusted HR for tertiles 2 and 3, the upper 2 tertiles were combined for comparison against tertile 1. Patients in the second and third tertiles of hs-CRP had a 1-year incidence of death, MI, or stroke of 11.4% compared with 6.4% in the first tertile (Pϭ0.003). There was also an increase in the 28-day primary end point for patients in the second and third tertiles when compared with the first (8.0% versus 5.1%, Pϭ0.04). Kaplan-Meier curves demonstrate that many events occurred within the first few days and that separations between biomarker-defined strata emerged in that time frame ( Figure 1A) .
Treatment with clopidogrel reduced the 1-year composite end point for patients in tertiles 2 and 3 as compared with placebo (9.1% versus 13.5%, Pϭ0.04). No difference in the 1-year end point was found between those randomized to clopidogrel or placebo in the lowest tertile of hs-CRP (6.4% versus 6.4%, Pϭ0.97; Figure 1B ). There was also no significant treatment effect for the 28-day end point within the second and third tertiles (Pϭ0.49) or within the first (Pϭ0.74).
After adjustment for baseline differences from the multivariable analysis, the top 2 tertiles of hs-CRP had an elevated hazard for the 1-year primary end point (HRϭ1.60, [1.01, 2.54], Pϭ0.045). When an interaction of treatment and hs-CRP was assessed, there was a trend toward benefit for patients in the top 2 tertiles who Figure 1B in that the relative positions of the clopidogrel and placebo curves do not differ significantly between tertile 1 and tertiles 2/3.
Pregnancy-Associated Plasma Protein-A and 28-Day and 1-Year Outcomes
As with hs-CRP, the primary 1-year event rates were lower in the first tertile of PAPP-A and higher for patients in the second and third tertiles, although the difference was not statistically significant (6.8%, 10.2%, and 10.2%, respectively, Pϭ0.18). The unadjusted HR for the 1-year primary end point were similar for patients in the second tertiles (HRϭ1.53, [0.91, 2.55], Pϭ0.11) and third tertiles (HRϭ1.54, [0.92, 2.58], Pϭ0.10) compared with the first. Therefore, tertiles 2 and 3 were again combined for comparison against the first. Elevated PAPP-A levels were associated with increased events at 1 year and 28 days, although the increases did not reach statistical significance ( Table 2) . As with hs-CRP, a separation in event rates by PAPP-A biomarker strata occurred within the first few days and continued out to 1 year (Figure 2A ). Patients in tertiles 2 and 3 for PAPP-A demonstrated a reduction in 1-year death, MI, or stroke when treated with clopidogrel as compared with placebo (7.3% versus 13.1%, Pϭ0.01). No significant difference by treatment was noted in 1-year events for patients in the first tertile (7.0% for clopidogrel versus 6.5% for placebo, Pϭ0.84; Figure 2B ) There was not a statistically significant difference noted in 28-day events by treatment group within the second and third or within the first tertile of PAPP-A. After adjustment for baseline differences by multivariable analysis, the top 2 tertiles of PAPP-A still did not have a significantly higher hazard for 1-year events than the first tertile (HRϭ1.5, [0.90, 2.5], Pϭ0.12). When an interaction of treatment and PAPP-A was assessed, there appeared to be a benefit for patients in the top 2 PAPP-A tertiles who received clopidogrel compared with placebo (HRϭ0.49, [0.28, 0.88]). There was no benefit with clopidogrel compared with placebo for those in the first (HRϭ1.60, [0.64, 4.0]; interaction Pϭ0.03). This significant interaction is graphically demonstrated in Figure 2b in that the relative positions of the clopidogrel and placebo curves differ significantly between tertile 1 and the top 2 tertiles.
Combined CRP and PAPP-A and 28-Day and 1-Year Outcomes
Patients in the second and third tertiles for both hs-CRP and PAPP-A (nϭ453) had a higher incidence of the 1-year composite end point when compared with those with 1 or both biomarkers in the first tertile (nϭ642; 12.5% versus 6.6%, PϽ0.001; Table 2 ). The 28-day primary end point also occurred more often for patients high on both biomarkers compared with patients low on at least 1 (9.8% versus 5.2%, Pϭ0.004). A separation in event rates by biomarkerdefined strata occurred within the first few days and continued throughout the year ( Figure 3A ). Patients with both biomarkers elevated experienced a reduction in 1-year death, MI, or stroke when treated with clopidogrel compared with placebo (8.7% versus 16.2%, Pϭ0.02). There was no significant difference in the 1-year composite end point for clopidogrel as compared with placebo-treated patients who were low on at least 1 biomarker (6.2% versus 7.0%, Pϭ0.73; Figure 3B ). As for the 28-day primary end point, no significant differences by treatment were noted either among patients high on both biomarkers or among patients low on at least 1 biomarker.
After adjusting for baseline differences by multivariable analysis, patients with both biomarkers elevated had a greater hazard for the 1-year composite end point compared with patients low on at least 1 biomarker (HRϭ1.68, [1.06, 2.66], Pϭ0.03). When an interaction was assessed, randomization to clopidogrel in patients with both biomar- Again the relative positions of the clopidogrel and placebo curves in Figure 3b differ significantly between tertile 1 and combined tertiles 2 and 3, graphically demonstrating this significant interaction probability value.
Discussion
This post hoc analysis of the CREDO study adds to existing literature showing that hs-CRP and PAPP-A may play an important role in predicting future cardiovascular events. More importantly, these data suggest that biomarkers including hs-CRP and PAPP-A may identify individuals more likely to benefit from a longer treatment duration of dual antiplatelet therapy with clopidogrel and aspirin after nonurgent PCI with a bare metal stent. Clopidogrel reduced the 1-year incidence of death, MI, or stroke by 33% for patients with hs-CRP levels Ն1.5 mg/L, by 44% for patients with PAPP-A levels Ն0.79 mIU/L, and by 46% for those patients with elevated levels of both markers (Figure 4 ). The benefit of clopidogrel was maintained after adjustment for baseline differences by multiple variable analysis except for the elevated hs-CRP cohort, although there is some uncertainty about this finding because of a large volume of missing data after pertinent variables were added to the Cox proportional hazards models.
Various studies have demonstrated the utility of hs-CRP in predicting future cardiovascular events. Data from the Physicians' Health Study demonstrated that elevated baseline hs-CRP was associated with an increase in MI or stroke independent of traditional risk factors, 22 and that aspirin therapy was only beneficial in those with the highest levels of hs-CRP. A trial of biomarkers from the Women's Health Study identified hs-CRP as a stronger predictor of future cardiovascular events than low-density lipoprotein cholesterol. 23 Chew et al have shown that clopidogrel therapy added to aspirin reduced 30-day death or MI after PCI for patients with a baseline elevated hs-CRP level. A recent analysis of 4 Intracoronary Stenting and Antithrombotic Regimen trials showed that hs-CRP predicted 1-year mortality and major adverse cardiovascular events for patients undergoing PCI after pretreatment with clopidogrel. 24 However, randomization to abciximab did not provide a specific benefit to patients with high hs-CRP. This CREDO substudy is of particular importance because it is the first to suggest benefit for maintenance dual antiplatelet therapy in post-PCI patients who have elevated hs-CRP and PAPP-A. The mechanism of this finding is not entirely clear. Unlike statins, which seem to directly lower hs-CRP levels, [25] [26] [27] the ability of cardioprotective doses of aspirin, clopidogrel, or both to lower hs-CRP has not been established. Platelets play an integral role in the inflammatory changes that lead to atherosclerosis. 28 They are activated by inflammatory mediators and propagate inflammation by the further release of inflammatory substances. 29 Aspirin exerts its antiinflammatory effect on platelets by acetylating and hence inhibiting cyclooxygenase, which prevents the production of thromboxane A2. Clopidogrel inhibits platelet activation by antagonizing the platelet P2Y 12 ADP receptor. In 1 early trial, aspirin reduced inflammatory cytokines and C-reactive protein in patients with stable angina. 30 The mechanism was postulated to be caused by a reduction in cyclooxygenase-mediated cell activation, proliferation, and release of cytokines. A later trial in peripheral artery disease patients demonstrated a reduction in platelet-mediated inflammatory markers for those treated with clopidogrel alone or combined with aspirin when compared with untreated patients. 31 A similar reduction in inflammatory markers was not seen with aspirin alone. Another more recent trial in acute coronary syndrome patients showed a reduction in platelet-released inflammatory mediators for those with a high baseline hs-CRP who were treated with clopidogrel in addition to aspirin. 32 In a PCI population, clopidogrel pretreatment added to aspirin reduced the expression of platelet inflammatory markers including CD40 ligand and CD62 P-selectin. 33 The benefit of more aggressive inhibition of platelet activation with dual antiplatelet therapy may be attributable to a direct, but not yet well-identified, antiinflammatory effect. Alternatively, patients with a higher inflammatory burden may derive a greater benefit because inflammatory cytokines can directly activate platelets, with several studies finding a direct relationship between inflammation and platelet function. 34 -36 It remains unclear whether any antiinflammatory effect of clopidogrel is fully indexed to its antiplatelet effect, particularly with the convergence of recent evidence for a highly variable and genomically influenced effect of clopidogrel on platelet suppression. 37
Clinical Implications
This study provides additional evidence that hs-CRP and PAPP-A may help predict cardiovascular events after PCI. More importantly, the data suggest that these biomarkers may help identify patients most likely to benefit from continued dual antiplatelet therapy including aspirin and clopidogrel after nonurgent PCI with a bare metal stent.
Study Limitations
The study is limited by its retrospective and post hoc nature. Also, categorizing inflammatory biomarkers into tertiles implicitly assumes that the 33rd and 67th percentiles define thresholds at which the benefits of treatment may change substantially. Although there is ample precedent for this assumption in the literature, other possibilities are that the thresholds should be elsewhere or that the benefits of treatment should change only gradually. If so, then an approach that treats the biomarker levels as continuous variables may provide further insight. Although we have not systematically pursued such an approach herein, Figure 5A and 5B displays risk estimates for the 1-year composite end point as functions of logarithmically transformed biomarker levels. In addition, because patients were not randomized to biomarker strata, there is some possibility that unmeasured confounding variables affected our assessments of the relationships between biomarkers and clinical outcomes, even in the multivariable models. Moreover, as stent thrombosis events were not specifically captured, no comment can be made regarding any potential interactions between baseline inflammatory status and randomized therapy in relation to stent thrombosis events.
Conclusions
Patients undergoing nonurgent PCI who have elevated levels of hs-CRP or PAPP-A are at increased risk for future cardiovascular events. Those with increased levels of these biomarkers also are most likely to benefit from treatment with long-term clopidogrel when added to aspirin. Further studies are needed to assess the predictive value of hs-CRP and PAPP-A in other populations including acute coronary syndromes and when drug eluting stents are used and to determine whether clopidogrel has an incremental benefit for patients in these groups when inflammatory biomarkers are increased. 
